Product Information
APLENZIN ER 348 MG TABLET is a brand product labeled by Bausch Health US LLC, priced at $93.5116 per EA under NDC 00187581130. Its NADAC has been published 330 times since May 13, 2015.
FDA first approved this application on Apr 23, 2008.
Strength
348 mg/1
Manufacturer
Bausch Health US LLCNDC
00187581130
Classification
Brand
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/17/2025
Active Ingredients
BUPROPION HYDROBROMIDEApproval Type
New Drug (NDA)
FDA Application
NDA022108FDA Approved
4/23/2008
On Market Since
4/23/2008
Pharmacological Classes
Price Statistics
The NADAC for APLENZIN ER 348 MG TABLET has been published 330 times since May 13, 2015, and over the history we have for it it has risen 232.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $93.5116 per EA |
|---|---|
| All-time high | $93.6147 (Aug 13, 2025) |
| All-time low | $28.1591 (May 13, 2015) |
| Median price | $72.8055 |
| Average price | $73.6910 |
| Largest weekly change | +106.1% (Jul 17, 2019) |
| Weeks tracked | 330 |
| Tracking since | May 13, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+20.4%
5Y
+38.4%
All
+232.1%
Last surveyed Oct 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the bupropion hydrobromide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch Health US LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bupropion hydrobromide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminoketone class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of APLENZIN ER 348 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for APLENZIN ER 348 MG TABLET, manufactured by Bausch Health US LLC, is $93.5116 per EA (NDC 00187581130), effective Oct 1, 2025.
How has the price of APLENZIN ER 348 MG TABLET changed over time?
Over the history we have for it, the NADAC for APLENZIN ER 348 MG TABLET has risen 232.1%. It has been tracked across 330 weekly CMS publications since May 13, 2015.
What are the highest and lowest recorded NADAC prices for APLENZIN ER 348 MG TABLET?
Since May 13, 2015, the NADAC for APLENZIN ER 348 MG TABLET has ranged from a low of $28.1591 (May 13, 2015) to a high of $93.6147 (Aug 13, 2025), with a median of $72.8055 per EA.
Are there cheaper alternatives to APLENZIN ER 348 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of APLENZIN ER 348 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures APLENZIN ER 348 MG TABLET?
APLENZIN ER 348 MG TABLET (NDC 00187581130) is labeled by Bausch Health US LLC, and CMS classifies it as a brand product.